tbuckley/cabot-search huggingface dataset:
ST-Elevation Myocardial Infarction Diagnosed After Hospital Admission
Authors: Ross F. Garberich, Jay H. Traverse, Michael T. Claussen, Gabriel Rodriguez, Anil K. Poulose, Ivan J. Chavez, Stephanie Rutten-Ramos, David A. Hildebrandt, Timothy D. Henry
Journal: Circulation (2014)

Treatment times for ST-elevation myocardial infarction (STEMI) patients presenting to percutaneous coronary intervention hospitals have improved dramatically over the past 10 years, particularly for patients using emergency medical services. Limited data exist regarding treatment times and outcomes for patients who develop STEMI after hospital admission.With the use of a comprehensive prospective regional STEMI program database, we evaluated the characteristics and outcomes for patients who develop STEMI after hospital admission. Of the 3795 consecutive STEMI patients treated by the use of the Minneapolis Heart Institute regional STEMI program from March 2003 to January 2013, 990 (26.1%) presented initially to the percutaneous coronary intervention facility, including 640 arriving via emergency medical services, 267 self/family driven, and 83 already admitted to the hospital. Patients with in-hospital presentation were older with higher body mass indexes, were more likely to have hypertension, and to present with pre-percutaneous coronary intervention cardiac arrest and cardiogenic shock. Door-to-balloon times (diagnostic ECG-to-balloon for in-hospital patients) were longer than for patients using emergency medical services (76 versus 51 minutes; P<0.001), but similar to self/family-driven patients (76 versus 66 minutes; P=0.13). In-hospital patients had longer lengths of stay (5 versus 3 versus 3 days; P<0.001) and higher 1-year mortality (16.9% versus 10.3% versus 7.1%; P=0.032). These patients frequently had high-risk and complex reasons for admission, including 30.1% with acute coronary syndrome, 22.9% postsurgery, 13.3% respiratory failure, and 8.4% ventricular fibrillation.Patients who develop STEMI while in-hospital represent a unique, high-risk subset of patients. They have increased treatment time and lengths of stay and higher mortality rates than the patients presenting via emergency medical services or who are self/family driven.
204. Substrate-Mediated Gene Delivery for Assessment of Signal Transduction Pathways in Cancer Cells
Authors: Angela K. Pannier, Zain Bengali, Eric A. Ariazi, V. Craig Jordan, Lonnie D Shea
Journal: Molecular Therapy (2005)

Gene delivery has the potential to be used in diagnostic applications, specifically to investigate cellular signal transduction pathways responsible for disease. Analysis of multiple pathways or genes in a parallel format can be achieved using a transfected cell array, a high throughput approach to correlate gene expression with functional cell responses, based on gene delivery from a substrate that supports cell adhesion. Substrate-mediated gene delivery functions by self-assembling DNA with nonviral vectors, resulting in positively charged complexes that can interact with a biomaterial or substrate. Cells cultured on the substrate are exposed to elevated DNA concentrations within the local microenvironment, which enhances transfection. DNA complexes can be immobilized on the substrate through specific interactions introduced through complementary functional groups on the vector and surface or through nonspecific interactions. As surface properties are critical to the efficiency of the surface delivery approach, self-assembled monolayers (SAMs) of alkanethiols on gold were used to study the mechanisms of transfection by complexes nonspecifically immobilized on chemically specific substrates. Surface hydrophilicity and ionization were found to mediate both immobilization and transfection. Additionally, SAMs were used in conjugation with soft lithographic techniques to imprint substrates with specific patterns of SAMs, resulting in patterned DNA complex deposition and transfection.
Soluble E‐selectin, other markers of inflammation and disease severity in children with atopic dermatitis
Authors: None Wolkerstorfer, None Laan, None Savelkoul, None Neijens, None Mulder, None Oudesluys‐Murphy, None Sukhai, None Oranje
Journal: British Journal of Dermatology (1998)

E-selectin, P-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) are membrane-bound adhesion molecules which mediate the attachment of leucocytes to endothelial cells. These molecules are preferentially expressed on activated endothelium. The soluble forms of these molecules (sE-selectin, sP-selectin, sICAM-1 and sVCAM-1) are present in the circulation as a result of shedding. Some of the soluble adhesion molecules have been thought to reflect disease activity in atopic dermatitis (AD). To evaluate their potential to reflect disease activity in AD, we correlated their plasma concentration with clinical severity measured by objective SCORAD (SCORing Atopic Dermatitis). Furthermore, levels of total IgE, specific IgE, and eosinophil cationic protein (ECP) were determined. SCORAD and sE-selectin levels were significantly increased in children with specific IgE for both food and inhalation allergens (P < 0.05). ECP consistently showed an increase with the scores of SCORAD, but no statistical significance was reached. Disease activity was significantly correlated with the plasma levels of sE-selectin (rs = 0.6, P < 0.0005) but not with sP-selectin, sICAM-1 and sVCAM-1. This agrees with recent studies performed in adults with AD, and supports the potential of sE-selectin as a parameter for monitoring disease activity in young children with AD.
Improvement of Impaired Myocardial Vasodilatation Due to Diffuse Coronary Atherosclerosis in Hypercholesterolemics After Lipid-Lowering Therapy
Authors: Ikuo Yokoyama, Shin-ichi Momomura, Tohru Ohtake, Katsunori Yonekura, Weidong Yang, Naoshi Kobayakawa, Teruhiko Aoyagi, Seiryo Sugiura, Nobuhiro Yamada, Kuni Ohtomo, Yasuhito Sasaki, Masao Omata, Yoshio Yazaki
Journal: Circulation (1999)

Background —Diminished myocardial vasodilatation (MVD) in hypercholesterolemics without overt coronary stenosis has been reported. However, whether the diminished MVD of angiographically normal coronary arteries in hypercholesterolemics can be reversed after lipid-lowering therapy is not known. Methods and Results —A total of 27 hypercholesterolemics and 16 age-matched controls were studied. All patients had &gt;1 normal coronary artery, and those segments that were perfused by anatomically normal coronary arteries were studied. Myocardial blood flow (MBF) was measured during dipyridamole loading and at baseline using positron emission tomography and 13 N-ammonia, after which MVD was calculated before and after lipid-lowering therapy. Total cholesterol was significantly higher in hypercholesterolemics (263±33.8) than in controls (195±16.6), and it normalized after lipid-lowering therapy (197±19.9). Baseline MBF (ml · min −1 · 100 g −1 ) was comparable among hypercholesterolemics (both before and after therapy) and controls. MBF during dipyridamole loading was significantly lower in hypercholesterolemics before therapy (189±75.4) than in controls (299±162, P &lt;0.01). However, MBF during dipyridamole loading significantly increased after therapy (226±84.7; P &lt;0.01). MVD significantly improved after therapy in hypercholesterolemics (2.77±1.35 after treatment [ P &lt;0.05] versus 2.02±0.68 before treatment [ P &lt;0.01]), but it remained significantly higher in controls (3.69±1.13, P &lt;0.01). There was a significant relationship between the percent change of total cholesterol and the percent change of MVD before and after lipid-lowering therapy ( r =−0.61, P &lt;0.05). Conclusions —Diminished MVD of anatomically normal coronary arteries in hypercholesterolemics can be reversed after lipid-lowering therapy.
A Question of Priority in Abortive Treatment of Typhoid Fever.
Authors: Arthur J. Hall
Journal: JAMA (1896)

Washington, D. C., March 12, 1896. <h3>To the Editor:</h3> —As reported in your paper, at the meeting of the Mississippi Valley Medical Association at Hot Springs, Nov. 21, 1894, Dr. Woodbridge expounded his so-called abortive treatment of typhoid fever, giving three polypharmic formulæ with instruction for their use, and claimed he had had twelve years experience with this treatment. The formulæ mentioned contain guaiacol carbonate to the extent of 33⅓ per cent. This claim of twelve years experience with guaiacol carbonate is at variance with a statement by the manufacturers of the drug, as follows: "In the<i>Allgemeine Medicinische Central-Zeitung</i>, 1893, Nos. 45 and 46, Dr. Fritz Hoelscher gives an interesting account of his experiences with guaiacol carbonate as an intestinal antiseptic, more especially in typhoid fever." From this it would seem, so far as the manufacturers knew, the drug had not been used in typhoid fever prior to 1893.
Polymyalgia and Minoxidil
Authors: R. Colamarino
Journal: Annals of Internal Medicine (1990)

Letters and Corrections1 August 1990Polymyalgia and MinoxidilR. Colamarino, J.J. Dubost, B. SauvezieR. ColamarinoSearch for more papers by this author, J.J. DubostSearch for more papers by this author, B. SauvezieSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-113-3-256_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors:Topical minoxidil has been commercially available since 1987 for the treatment of baldness. Except for contact dermatitis, it is considered free of adverse reactions (1). Reports of hypertrichosis (2) in parts of the body remote from the site of application and rare cases of nerve or cardiovascular toxicity (3-5), however, suggested the possibility of systemic side effects. We observed a previously unreported "polymyalgia" syndrome in four of our patients on topical minoxidil. All were healthy men, aged 48, 40, 40, and 27, respectively. Topical minoxidil was their only medication; they applied it from twice a day to...References1. Alomar A. Allergic contact dermatitis from minoxidil. Contact Dermatitis. 1988;18:51-2. CrossrefMedlineGoogle Scholar2. Baral J. Minoxidil and tail-like effect. Int J Dermatol. 1987;26:480. CrossrefMedlineGoogle Scholar3. Horsepian P. Minoxidil induced pericardial effusion. J Ky Med Assoc. 1988;86:235-7. MedlineGoogle Scholar4. Leenen F, Smith D, and Unger W. Topical minoxidil: cardiac effects in bald men. Br J Clin Pharmacol. 1988;26:481-5. CrossrefMedlineGoogle Scholar5. Tunkel A, Shuman M, Popkin M, Seth R, and Hoffman B. Minoxidilinduced systemic lupus erythematosus. Arch Intern Med. 1987;147: 599-600. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: R. Colamarino; J.J. Dubost; B. SauvezieAffiliations: Hôpital Saint-Jacques 63003 Clermont-Ferrand France PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMinoxidil-Associated Anorexia in an Infant with Refractory HypertensionDRUG-RELATED MYOPATHIESEvaluation of Oral and Topical Minoxidil Exposures Reported to US Poison Centres from 1985–1991Dermatological drugs, topical agents and cosmeticsDermatologic therapy: 1990Drug-induced myopathies 1 August 1990Volume 113, Issue 3 Page: 256-257 Keywords Adverse reactions Contact dermatitis Nerves Toxicity ePublished: 1 December 2008 Issue Published: 1 August 1990 PDF downloadLoading ...
Loss of <i>Rassf1a</i> Synergizes with Deregulated Runx2 Signaling in Tumorigenesis
Authors: Louise van der Weyden, Angelos Papaspyropoulos, George Poulogiannis, Alistair G. Rust, Mamunur Rashid, David J. Adams, Mark J. Arends, Eric O'Neill
Journal: Cancer Research (2012)

The tumor suppressor gene RASSF1A is inactivated through point mutation or promoter hypermethylation in many human cancers. In this study, we conducted a Sleeping Beauty transposon-mediated insertional mutagenesis screen in Rassf1a-null mice to identify candidate genes that collaborate with loss of Rassf1a in tumorigenesis. We identified 10 genes, including the transcription factor Runx2, a transcriptional partner of Yes-associated protein (YAP1) that displays tumor suppressive activity through competing with the oncogenic TEA domain family of transcription factors (TEAD) for YAP1 association. While loss of RASSF1A promoted the formation of oncogenic YAP1-TEAD complexes, the combined loss of both RASSF1A and RUNX2 further increased YAP1-TEAD levels, showing that loss of RASSF1A, together with RUNX2, is consistent with the multistep model of tumorigenesis. Clinically, RUNX2 expression was frequently downregulated in various cancers, and reduced RUNX2 expression was associated with poor survival in patients with diffuse large B-cell or atypical Burkitt/Burkitt-like lymphomas. Interestingly, decreased expression levels of RASSF1 and RUNX2 were observed in both precursor T-cell acute lymphoblastic leukemia and colorectal cancer, further supporting the hypothesis that dual regulation of YAP1-TEAD promotes oncogenic activity. Together, our findings provide evidence that loss of RASSF1A expression switches YAP1 from a tumor suppressor to an oncogene through regulating its association with transcription factors, thereby suggesting a novel mechanism for RASSF1A-mediated tumor suppression.
Abstract 2501: Differential protein signatures in cancer cell lines after dosing with anticancer molecules in vitro and in vivo.
Authors: Robert Swift, Deb Ayers, Ying Chang, Darryl Perry, Sheri Routt, Sheri Wilcox, Bridget Lollo, Nick Saccomano
Journal: Cancer Research (2013)

Abstract Using a sensitive proteomics platform that can precisely and simultaneously measure 1129 distinct proteins (SOMAscan™), we profiled the proteomic changes in cancer cell lines and xenograft models following exposure to several oncological agents. Our goals were to identify novel biomarkers and drug targets, and to map out pharmacological MOA, with the ultimate goal of assessing the translatability of in vitro and preclinical models to human patients. We have generated multiple successful examples of using our platform in this manner. We treated a breast cancer cell line MCF-7 with eight pharmacological agents, including TamoxifenTM and TaxolTM. We have assessed PKC-δ resistant and sensitive lung cancer cell lines with a PKC-δ inhibitor, and profiled protein changes in response to these compounds. To assess how well in vitro models translate to preclinical models, we profiled protein changes in HCC827 (sensitive) or H1299 (resistant) cell lines treated with erlotinib (TarcevaTM), and NOD/SCID mice implanted with HCC827 cells and dosed with erlotinib. We observed good concordance of the protein changes in the HCC827 cell-lines and the xenograft models, which included cyclin A and p27KIP1 expression levels (proteins previously associated with erlotinib sensitivity) as well as additional protein changes with highly plausible connections to erlotinib's mode of action. These newly identified proteins may have implications for treating patients that develop resistance to erlotinib in the clinic, and suggest new targets for drug development. A human clinical study is underway to explore how the proteomic changes seen in this study translate to erlotinib treatment of NSCLC patients in the clinic. Citation Format: Robert Swift, Deb Ayers, Ying Chang, Darryl Perry, Sheri Routt, Sheri Wilcox, Bridget Lollo, Nick Saccomano. Differential protein signatures in cancer cell lines after dosing with anticancer molecules in vitro and in vivo. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2501. doi:10.1158/1538-7445.AM2013-2501 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
PATTERNS OF SYSTOLIC AND DIASTOLIC LEFT VENTRICULAR DEFORMATION IN OLYMPIC ATHLETES
Authors: Stefano Caselli, Dalma Montesanti, Fernando Di Paolo, Pisicchio Cataldo, Barbara Di Giacinto, Filippo Quattrini, beatrice musumeci, Camillo Autore, Natesa Pandian, Antonio Pelliccia
Journal: Journal of the American College of Cardiology (2014)
186. Efficient In Vivo Gene Expression by DNA/ Polycation/Polyanion Ternary Complexses
Authors: Tomoko Ito, Keiko Abe, Chieko Yoshihara, Naoko Iida Tanaka, Yoshiyuki Koyama
Journal: Molecular Therapy (2006)

A variety of DNA/polycation complexes have been explored as synthetic vectors, and several polycations have been already realized effective gene transfer in cultured cells. However, there still remain problems for therapeutic applications of these synthetic gene delivery systems. One of the major obstacles to their application to in vivo gene therapy would be their undesirable interaction with blood cells, serum proteins, and extracellular matrices, with which the DNA complexes would contact before reaching to target cell surfaces. In order to achieve high stability in the blood stream, and target specificity, the positive charge should be shielded. We have reported that hyaluronic acid (HA) and PEG-Cs, a new type of PEG derivatives bearing carboxylic acid pendants, could deposit onto the positively charged DNA/polycation complex, and recharge it to negative (Fig. 1). Moreover, these polyanions were revealed to loosen the tightly compacted DNA/polycation complex to facilitate the approach of transcription factors, and highly improve the transcriptional efficiency. Effective in vivo transgene expression by the DNA/polycation complexes coated by these polyanions was attempted. Results and Discussion Mice were subcutaneously inoculated with CHO cells, which are known to express a receptor to HA, and plasmid/PEI/HA ternary complex was intratumoraly injected. The HA-coated complex showed high transgene expression, while plasmid/PEI binary complex exhibited very low transfection efficiency. When fluorescent-labeled plasmid/PEI/HA (or PEG-C) ternary complex was injected into peritoneal cavity of mice, it showed fine distribution throughout the cavity. B16 mouse melanoma cells were then intraperitoneally inoculated in mice. As expected, plasmid/PEI complex coated by HA showed high transfection efficiency, and much higher gene expression in tumor was observed than in the normal cells. Those coated by ligand-bearing PEG-Cs also showed high gene expression in the tumor cells. Polyampholytes was found to have superior transcriptional enhancing effect. The amphoteric HA derivative (Spn-HA) was prepared by introducing spermine side chains to HA. The complex with Spn-HA mediated higher transfection levels in the subcutaneously inoculated CHO cells than with the original HA (Fig. 2).
ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: Executive Summary and Recommendations
Authors: Kim A. Eagle, Robert A. Guyton, Ravin Davidoff, Gordon A. Ewy, James Fonger, Timothy J. Gardner, John Parker Gott, Howard C. Herrmann, Robert A. Marlow, William Nugent, Gerald T. O’Connor, Thomas A. Orszulak, Richard E. Rieselbach, William L. Winters, Salim Yusuf, Raymond J. Gibbons, Joseph S. Alpert, Kim A. Eagle, Timothy J. Gardner, Arthur Garson, Gabriel Gregoratos, Richard O. Russell, Thomas J. Ryan, Sidney C. Smith
Journal: Circulation (1999)

HomeCirculationVol. 100, No. 13ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: Executive Summary and Recommendations
Concordance for coronary risk factors among spouses.
Authors: D L Sackett, G D Anderson, R Milner, M Feinleib, W B Kannel
Journal: Circulation (1975)

Values for several coronary risk factors, including systolic and diastolic blood pressure, serum cholesterol, triglycerides, blood glucose, uric acid, hemoglobin, weight, vitral capacity and cigarette smoking have been found to be similar among spouses in the Framingham Study. However, longitudinal analyses show that this spouse concordance does not increase over a twelve-year observation period, suggesting that it has arisen through the marriage of similar people rather than through the sharing of a common marital environment. Apparent conflicts between cross-sectional and longitudinal findings have been resolved by showing that spouses who were concordant at the begining of the study are more likely to survive to later exams, while discordant spouse pairs tend to be dissolved through the death of one of their members.
[36] EVOLUTION OF AETIOLOGY AND OUTCOME IN THE LAST 20 YEARS IN 500 PATIENTS WITH ACUTE LIVER FAILURE. FACTORS PREDICTIVE OF SURVIVAL AND OF NEUROLOGICAL SEQUELLAE
Authors: P. Ichai, L.C. Faria, A. Letierce, F. Saliba, D. Azoulay, T. Antonini, S. Ben Hamida, R. Adam, H. Bismuth, L. Becquemont, D. Castaing, D. Samuel
Journal: Journal of Hepatology (2007)
Toward an Ego Psychological Appraisal of Drug Effects
Authors: LEOPOLD BELLAK, MARVIN HURVICH, MARK SILVAN, DAVID JACOBS
Journal: American Journal of Psychiatry (1968)

After reviewing various strategies of drug appraisal, the authors suggest a psychodynamic approach to the assessment of psychotropic drugs. They present ten ego functions and their component factors, as well as examples of how the functions are assessed from interviews, clinical psychological tests, and psychological laboratory procedures. Suggestions are offered for the use of these ego function measures in drug evaluation research.
Toward Evidence-Based Statistics
Authors: Jean-Francois Caubet
Journal: Annals of Internal Medicine (2000)

Letters21 March 2000Toward Evidence-Based StatisticsJean-Francois Caubet, MD, MSJean-Francois Caubet, MD, MSMassachusetts General Hospital; Boston, MA 02114 (Caubet)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-6-200003210-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Goodman (1, 2) and Davidoff (3) have written superb essays on Bayesian statistics. What could be the next step?Pharmaceutical companies engaged in clinical research programs, and physicians prescribing treatments to patients, reach decisions to proceed or not proceed after considering several variables. Efficacy is one. Others are side effects, costs, and competing treatments. These are considered prospectively for the design of a clinical trial (alternative hypothesis and sample size) and before the initiation of a treatment. A challenge for Bayesian analysis will be to incorporate these dimensions into the analyses, and advanced methods such as influence ...References1. Goodman SN. Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med. 1999;130:995-1004. LinkGoogle Scholar2. Goodman SN. Toward evidence-based medical statistics. 2: The Bayes factor. Ann Intern Med. 1999;130:1005-13. LinkGoogle Scholar3. Davidoff F. Standing statistics right side up [Editorial]. Ann Intern Med. 1999;130:1019-21. LinkGoogle Scholar4. Owens DK, Shachter RD, Nease R. Representation and analysis of medical decision problems with influence diagrams. Med Decis Making. 1997;17:241-62. CrossrefMedlineGoogle Scholar5. Muller P, Insua DR. Issues in Bayesian analysis of neural network models. Neural Comput. 1998;10:749-70. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Massachusetts General Hospital; Boston, MA 02114 (Caubet) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoToward Evidence-Based Medical Statistics. 1: The P Value Fallacy Steven N. Goodman Toward Evidence-Based Medical Statistics. 2: The Bayes Factor Steven N. Goodman Standing Statistics Right Side Up Frank Davidoff Toward Evidence-Based Statistics Daniel P. Sulmasy Toward Evidence-Based Statistics Thomas Morgan Metrics Cited ByThe application of special technologies in diagnostic anatomic pathology: is it consistent with the principles of evidence-based medicine? 21 March 2000Volume 132, Issue 6Page: 507-508KeywordsAlgorithmsBayesian methodClinical trialsNeural networksPatients Issue Published: 21 March 2000 CopyrightCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...